



Item 8.01 Other Events.

On June 25, 2012, Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), issued a press release announcing that the dosing of a first patient in its Phase 2b juvenile clinical trial evaluating the safety and potential efficacy of RP103 as a potential treatment of non-alcoholic steatohepatitis, an advanced form of non-alcoholic fatty liver disease. RP103 is the Company's proprietary delayed-release microbead formulation of cysteamine bitartrate. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit	Filed
No.	Here Incorporated by Reference
Exhibit Description	with Form File No. Exhibit Filing Date Filed By
99.1	Press release issued by the Company dated as of June 25, 2012 X

---

Edgar Filing: Raptor Pharmaceutical Corp - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RAPTOR PHARMACEUTICAL CORP.

Date: June 25, 2012    By:    /s/ Kim R. Tsuchimoto  
Name: Kim R. Tsuchimoto  
Title: Chief Financial Officer, Treasurer and Secretary

---

Edgar Filing: Raptor Pharmaceutical Corp - Form 8-K

Exhibit Index

Exhibit	No.	Exhibit Description	Filed Here Incorporated by Reference with FormFile No. Exhibit Filing Date Filed By
	99.1	Press release issued by the Company dated as of June 25, 2012 X	